- Stock markets drift lower as US jobs data looms
- Pakistan flight departs for Paris after EU ban lifted
- Nobel laureate Malala Yousafzai to visit native Pakistan for girls' summit
- AI comes down from the cloud as chips get smarter
- Tajikistan bets on giant dam to solve electricity crisis
- Uruguay bucks 2024 global warming trend
- Last 2 years crossed 1.5C global warming limit: EU monitor
- Japan 'poop master' gives back to nature
- US Supreme Court to hear TikTok ban case
- US Fed's December rate cut should be its last for now: official
- Paris Hilton among celebrities to lose homes in LA fires
- Airbus boosts plane deliveries in 2024
- Ubisoft reviews restructuring options, postpones new Assassin's Creed
- Lamborghini sets new sales record amidst hybrid push
- Lebanon army chief Aoun becomes president after two-year vacancy
- US emissions stagnated in 2024, challenging climate goals: study
- Lebanon army chief short of required majority in first round of president vote
- Global stock markets mixed tracking US rates outlook
- Lebanon meets to finally elect president after two-year vacancy
- Celebrities flee Los Angeles fires, lose houses as Hollywood events scrapped
- Japan startup hopeful ahead of second moon launch
- Ukraine allies to hold last defence meet before Trump takes office
- Myanmar military adopts anti-junta fighters' drone tactics
- CES tech looks to help world's aging population
- Rubber tappers forge sustainable future in Amazon
- US astronauts upbeat seven months into eight-day mission
- Extreme weather, suburban sprawl fuel LA's wildfires
- Political chess or true beliefs? Zuckerberg's surprise Trump pivot
- US Fed officials concerned over 'stalled' disinflation, tariffs: minutes
- Celebrities flee Los Angeles fires as Hollywood events scrapped
- Several US Fed officials concerned over 'stalled' disinflation: minutes
- US tech titans ramp up pressure on EU
- 'Wicked' tops SAG Awards nominations
- Safe from looting, Damascus museum reopens a month after Assad's fall
- Award-winning migrant actor earns visa to stay in France -- as a mechanic
- Celebrities forced to flee Los Angeles blazes
- US tariff and inflation fears rattle global markets
- US private sector hiring undershoots expectations: ADP
- US tariffs unlikely to have 'significant' inflation impact: Fed official
- Lebanon leaders in talks for new bid to elect president
- Antarctic sea ice rebounds from record lows: US scientists
- Can EU stand up to belligerent Big Tech in new Trump era?
- US, Canadian and Australian travellers now face UK entry fee
- Indonesia upholds iPhone 16 sales ban after Apple offers $1 bn investment
- UK's Catherine turns 43 hoping for better year
- OpenAI chief Sam Altman denies sister's sexual abuse accusations
- Germans turn to balcony solar panels to save money
- Samsung warns fourth-quarter profit to miss forecasts
- Brazil gears up for first climate conference in Amazon
- Iraqi archaeologists piece together ancient treasures ravaged by IS
Once-taboo ketamine booms for US at-home mental care
Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.
A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.
Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.
"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."
Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.
It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.
In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.
- Ketamine 'babysitter' -
Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.
An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.
Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.
"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.
For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.
Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.
"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.
Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.
- 'Change your life' -
US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.
Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.
He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.
"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.
Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.
Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.
Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.
"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.
M.Davis--CPN